These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 2351926)
61. [Giant-cell arteritis with initial resistance to corticosteroids (author's transl)]. Treves R; Gerbaud A; Catanzano G; Desproges-Gotteron R Sem Hop; 1982 Jan; 58(1):13-5. PubMed ID: 6275541 [TBL] [Abstract][Full Text] [Related]
62. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. Reid DM; Hughes RA; Laan RF; Sacco-Gibson NA; Wenderoth DH; Adami S; Eusebio RA; Devogelaer JP J Bone Miner Res; 2000 Jun; 15(6):1006-13. PubMed ID: 10841169 [TBL] [Abstract][Full Text] [Related]
64. [Natural history of corticosteroid-induced lipodystrophy: a prospective follow-up of 37 patients]. Fardet L; Flahault A; Kettaneh A; Tiev KP; Tolédano C; Cabane J Rev Med Interne; 2007 Dec; 28(12):825-31. PubMed ID: 17959276 [TBL] [Abstract][Full Text] [Related]
65. Do steroids increase lymphoma risk? A case-control study of lymphoma risk in polymyalgia rheumatica/giant cell arteritis. Askling J; Klareskog L; Hjalgrim H; Baecklund E; Björkholm M; Ekbom A Ann Rheum Dis; 2005 Dec; 64(12):1765-8. PubMed ID: 15843445 [TBL] [Abstract][Full Text] [Related]
66. Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial. Jover JA; Hernández-García C; Morado IC; Vargas E; Bañares A; Fernández-Gutiérrez B Ann Intern Med; 2001 Jan; 134(2):106-14. PubMed ID: 11177313 [TBL] [Abstract][Full Text] [Related]
67. Impact of antiplatelet therapy in the development of severe ischemic complications and in the outcome of patients with giant cell arteritis. Narváez J; Bernad B; Gómez-Vaquero C; García-Gómez C; Roig-Vilaseca D; Juanola X; Rodriguez-Moreno J; Nolla JM; Valverde J Clin Exp Rheumatol; 2008; 26(3 Suppl 49):S57-62. PubMed ID: 18799055 [TBL] [Abstract][Full Text] [Related]
68. A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study. Bernstein CN; Seeger LL; Anton PA; Artinian L; Geffrey S; Goodman W; Belin TR; Shanahan F Aliment Pharmacol Ther; 1996 Oct; 10(5):777-86. PubMed ID: 8899087 [TBL] [Abstract][Full Text] [Related]
69. Comparison of calcaneal ultrasound and DXA to assess the risk of corticosteroid-induced osteoporosis: a cross-sectional study. Javaid MK; McCrudden PR; Taylor P; Petley GW; Stroud M; Fine DR; Cooper C; Arden NK Osteoporos Int; 2001; 12(9):788-93. PubMed ID: 11605746 [TBL] [Abstract][Full Text] [Related]
70. The use of corticosteroid agents in connective tissue disorders. Barraclough D Med J Aust; 1986 Apr; 144(8):427-32. PubMed ID: 2870416 [No Abstract] [Full Text] [Related]
71. Thromboembolic complications during corticosteroid treatment of temporal arteritis. Wadman B; Werner I Lancet; 1972 Apr; 1(7756):907. PubMed ID: 4111867 [No Abstract] [Full Text] [Related]
72. Impact of cranial and axillary/subclavian artery involvement by color duplex sonography on response to treatment in giant cell arteritis. Czihal M; Piller A; Schroettle A; Kuhlencordt P; Bernau C; Schulze-Koops H; Hoffmann U J Vasc Surg; 2015 May; 61(5):1285-91. PubMed ID: 25659455 [TBL] [Abstract][Full Text] [Related]
73. Open-label pilot study comparing quantitative ultrasound and dual-energy X-ray absorptiometry to assess corticosteroid-induced osteoporosis in patients with chronic kidney disease. Grabe DW; Chan M; Eisele G Clin Ther; 2006 Feb; 28(2):255-63. PubMed ID: 16678647 [TBL] [Abstract][Full Text] [Related]
74. Prevention of glucocorticoid morbidity in giant cell arteritis. Buttgereit F; Matteson EL; Dejaco C; Dasgupta B Rheumatology (Oxford); 2018 Feb; 57(suppl_2):ii11-ii21. PubMed ID: 29982779 [TBL] [Abstract][Full Text] [Related]
75. Restricted dose and duration of corticosteroid treatment in patients with polymyalgia rheumatica and temporal arteritis. Lundberg I; Hedfors E J Rheumatol; 1990 Oct; 17(10):1340-5. PubMed ID: 2254893 [TBL] [Abstract][Full Text] [Related]
76. Steroid use is associated with clinically irrelevant biopsies in patients with suspected giant cell arteritis. Thomassen I; den Brok AN; Konings CJ; Nienhuijs SW; van de Poll MC Am Surg; 2012 Dec; 78(12):1362-8. PubMed ID: 23265125 [TBL] [Abstract][Full Text] [Related]
77. Corticosteroid-induced osteoporosis prevention: longitudinal practice patterns in The Netherlands 2001-2005. Duyvendak M; Naunton M; Atthobari J; van den Berg PB; Brouwers JR Osteoporos Int; 2007 Oct; 18(10):1429-33. PubMed ID: 17323108 [TBL] [Abstract][Full Text] [Related]
78. Management of giant cell arteritis. Our 27-year clinical study: new light on old controversies. Hayreh SS; Zimmerman B Ophthalmologica; 2003; 217(4):239-59. PubMed ID: 12792130 [TBL] [Abstract][Full Text] [Related]
79. [Benefits of corticosteroids in the treatment of Horton's disease and rhizomelic pseudopolyarthritis: advantages and inconveniences. A meta-analysis]. Généreau T; Cabane J Rev Med Interne; 1992; 13(5):387-91. PubMed ID: 1344839 [TBL] [Abstract][Full Text] [Related]
80. Corticosteroid effects on proximal femur bone loss. Sambrook P; Birmingham J; Kempler S; Kelly P; Eberl S; Pocock N; Yeates M; Eisman J J Bone Miner Res; 1990 Dec; 5(12):1211-6. PubMed ID: 2075834 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]